Document Detail


Tirofiban for myocardial infarction.
MedLine Citation:
PMID:  20210689     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
IMPORTANCE OF THE FIELD: Inhibition of platelet aggregation plays a key role in treatment of coronary artery disease. AREAS COVERED IN THIS REVIEW: Studies on the effects of tirofiban in patients with either ST elevation or non-ST elevation myocardial infarction are reviewed. WHAT THE READER WILL GAIN: Tirofiban is a small-molecule glycoprotein IIb/IIIa receptor inhibitor. If discontinued, the action of tirofiban is faster reversed as abciximab. The dose varied between low (bolus of 0.4 microg/kg administered over 30 min followed by an infusion of 0.10 microg/kg/min), intermediate (bolus of 10 microg/kg administered over 3 min followed by an infusion of 0.15 microg/kg/min) and high (bolus of 25 microg/kg administered over 3 min followed by an infusion of 0.15 microg/kg/min). The high-dose administration especially may be beneficial in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention (PCI). There is no indication for tirofiban in patients treated with thrombolysis. Patients with non-ST elevation myocardial infarction requiring PCI are most likely to benefit from tirofiban if they have ongoing ischemia and/or dynamic ECG changes. The risk of serious bleeding with tirofiban is low and there is a very low risk of thrombocytopenia. TAKE HOME MESSAGE: Use of tirofiban for myocardial infarction is effective and has an acceptable safety profile.
Authors:
Yahya B Juwana; Harry Suryapranata; Jan Paul Ottervanger; Arnoud W J van 't Hof
Related Documents :
24327469 - Correlation between cardiac tissue doppler and peripheral vascular doppler in the anemi...
20691839 - Cost and health outcome of primary percutaneous coronary intervention versus thrombolys...
24356239 - Nod2 deficiency protects against cardiac remodeling after myocardial infarction in mice.
23383329 - Phenotyping of left and right ventricular function in mouse models of compensated hyper...
23960599 - The basics of echocardiography.
23143329 - Short- and long-term individual variation in cardiac troponin in patients with stable c...
23960589 - Prevalence and clinical significance of heart murmurs detected in routine neonatal exam...
1290639 - Functional significance of premature ventricular complex morphology evaluated during tr...
20101359 - Cardiac arrest caused by undersensing of a temporary epicardial pacemaker.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  11     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-03-09     Completed Date:  2010-06-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  861-6     Citation Subset:  IM    
Affiliation:
Hospital Cinere, Cardiovascular Center, Jakarta, Indonesia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angioplasty, Transluminal, Percutaneous Coronary / methods
Dose-Response Relationship, Drug
Electrocardiography
Hemorrhage / chemically induced
Humans
Myocardial Infarction / drug therapy*,  physiopathology
Platelet Aggregation Inhibitors / administration & dosage,  adverse effects,  therapeutic use*
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
Thrombocytopenia / chemically induced
Tyrosine / administration & dosage,  adverse effects,  analogs & derivatives*,  therapeutic use
Chemical
Reg. No./Substance:
0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 144494-65-5/tirofiban; 55520-40-6/Tyrosine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Topical n-docosanol for management of recurrent herpes labialis.
Next Document:  Alginate as an immobilization material for MAb production via encapsulated hybridoma cells.